MINI FUTURE LONG - ZEALAND PHARMA | Market Closed - Börse Stuttgart 02:31:42 2024-05-24 pm EDT | ||
| 3.49 EUR | -5.93% |
|
| Current month | -14.88% | ||
| 1 month | -15.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 3.49 | -5.93% |
| 24-05-23 | 3.71 | -2.11% |
| 24-05-22 | 3.79 | +0.80% |
| 24-05-21 | 3.76 | +3.87% |
| 24-05-20 | 3.62 | -1.09% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 02:31 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | ME6R7A |
| ISIN | DE000ME6R7A1 |
| Date issued | 2024-01-10 |
| Strike | 319.6 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.17 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.01 € |
|---|---|
| Lowest since issue | 1.35 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
586.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+33.94%
- Stock Market
- Certificates
- Certificat
